

1 **Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a,**
2 **double-blind, randomised, controlled phase 3 trial**

3

4 **Supplementary Materials**

5	Table 1. The COVAXIN Study Group	page 2
6	Reverse transcription polymerase chain reaction (RT-PCR)	page 5
7	Enzyme-linked immunosorbent assay (ELISA) at Screening	page 6
8	Enzyme-linked immunosorbent assay (ELISA) for lot-to-lot comparisons	page 6
9	Next-Generation Sequencing method	page 7
10	Microneutralisation method	page 8
11	ELISA Assays for S1 protein, RBD and N-antigen of SARS-COV-2	page 9
12	Table 2. Participants disposition status	page 10
13	Figure 1. Geometric mean ratios of MNT ₅₀ for three consecutive vaccine lots	page 11
14	Table 3. Geometric mean MNT ₅₀ by age, gender and baseline serostatus	page 12
15	Table 4. Summary of adverse events	page 13
16	Table 5. Incidences of solicited adverse events after each dose	page 14
17		

Supplementary table 1: COVAXIN Study Group and Ethic Committees from all participating trial sites				
Hospital Name, City, State	Ethics Committee Number	Principal Investigator	Co-Principal Investigator	Study Coordinators/Field Worker/Nurse
Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, Maharashtra	ECR/175/Inst/MH/2013/RR-19	Nilkanth Awad, MD	1) Siddharth Waghmare, MD 2) Vaibhav Aglawe, MD 3) Jairaj Nair, MD	1) Bhavika Jain 2) Chaitali Babar 3) Poonam Kabale 4) Akash Dhoble 5) Ankur Humare
Grant Government Medical College and Sir J.J Group of Hospitals, Mumbai, Maharashtra	ECR/382/Inst/MH/2013/RR-19	Priti Meshram, MD	1) Dinesh Dhodi, MD 2) Manali Vable, MD 3) Archana Bandkar, MD	1) Mehul Shah 2) Zainab Shaikh 3) Sabir Khan 4) Alex Pandit 5) Smruti Chalke
People's College of Medical Sciences and Research Centre And Associated People's Hospital, Bhopal, Madhya Pradesh	ECR/519/Inst/MP/2014/RR-17	Raghvendra Gumashta, MD	1) Sushil Jindal, MD 2) Chittaranjan Chaubal, MD 3) Sanjay Tandon, MD	1) Saroj Mani 2) Anjlika Jhariya 3) Namrata Manjhi 4) Richa Jain
Nizam's Institute of Medical Sciences, Punjagutta Market, Hyderabad	ECR/303/INST/AP/2013/RR-19	Prabhakar Reddy, MD	1) Ruby Raphael, MD 2) V Bhavani, MD 3) Abid Ali, MD	1) G. Devika 2) Lanka Tejaswi
Gujarat Medical Education and Research Society Medical College and Civil Hospital, Sola, Ahmedabad, Gujarat	ECR/404/Inst/GJ/2013/RR-20	Parul Bhatt, MD	1) Kiran Rami, MD 2) Rashmi Sharma, MD 3) Meera Shah, MD	1) Smruti Parekh 2) Vaishali Chauhan 3) Viraj Salvi 4) Anuj Tarpara 5) Dhaval Kumpavat
Indian Council of Medical Research, National Institute of Cholera and Enteric Diseases, Kolkata, West Bengal	ECR/416/Inst/WB/2013/RR-20	Suman Kanungo, MD	1) Shanta Dutta, MD 2) Agniva Majumdar, MD 3) Jaayanta Saha, MBBS	1) Snehasish Saha 2) Rupesh Mishra 3) Abhijit Guha 4) Dipak Das 5) Arpan Mitra
Institute of Medical Sciences and SUM Hospital, Bhubaneswar, Odisha	ECR/627/Inst/OR/2014/RR-17	Venkat E Rao, MD	1) Jyotiranjana Sahoo, MD 2) Smaraki Mohanty, MD 3) Sandeep Kumar Panigrahi, MD	1) Sahazad Ali 2) Banajini Pradhan 3) Manini Sahoo 4) Perween Sultana 5) Binata Samal
All India Institute of Medical Sciences, Patna, Bihar	ECR/1387/INST/BR/2020	Chandramani Singh, MD	1) Sanjay Pandey, MD 2) Pragya Kumar, MD 3) Yogesh Kumar, MD	1) Sarvesh Singh 2) Nitin Kr Singh 3) Achal Singh 4) Shreekant Kumar
Jeevan Rekha Hospital, Belgaum, Karnataka	ECR/1242/INST/KA/2019	Amit Bhate, MD	1) Suresh Bhate, MD 2) Paritosh Desai, MD 3) Abhishek Chavan, MD	1) Ajay Kunal 2) Imran Mulla 3) Sameer Nadaf 4) Laxman Arabhavi 5) Shoiab Shaikh
SRM Medical College and Research Centre, SRM	ECR/431/INST/TL/2013/RR-19	Satyajit Mohapatra, MD	1) Melvin George, MD 2) Balaji Ramraj, MD	1) Tharunya Palanivel 2) Kalai Selvi 3) Indiraa Priyadarshini

BBV152-Phase 3 Clinical Trial

Nagar, Kattankulathur, Tamilnadu			3) Gayathri Balasubramaniam, MD	4) Kamatchi 5) Anusuya
All India Institute of Medical Sciences, Patna, New Delhi	ECR/547/INST/DL/2014/RR-17	Sanjay Rai, MD	1) Randeep Guleria, MD 2) Shashi Kant, MD 3) Praveen Aggarwal, MD	1) Shreya Jha, 2) Suprakash Mandal 3) Tripti Rai 4) Priyanka Bansal 5) Akshay Sharma 6) Kirti Diswar
Prakhar Hospital, Kanpur, Uttar Pradesh	ECR/1017/INST/UP/2017	Jitendra Singh, MD	1) V Tripathi, MD 2) Vikas Mishra, MD 3) Anit Singh, MD	1) Nidhi Singh 2) Astha Singh 3) Saumya Singh 4) Sandeep Uniyal 5) Dev Chaudhary
Rahate Surgical Hospital and ICU, Nagpur, Maharashtra	ECR/601/Inst/MH/2014/RR-17	Manish Multani, MD	1) Prashant Rahate, MS	1) Ashish Tajne 2) Vaishali Tajne 3) Vrushali Mohitkar 4) Pravina Lanjewar 5) Megha Balbudhe
Vydehi Institute of Medical Sciences and Research, Bengaluru, Karnataka	ECR/747/Inst/KA/2015/RR-18	Akshatha Savith, MD	1) Gummadi Reddy, MD 2) Chalapathy DV, MD 3) Natesh Rao, MD	1) Nripesh Nepal 2) Khushboo Sharma 3) Hasina Taj 4) Arun Kumar 5) Payel Sarkar
Mahatma Gandhi Medical College and Research Institute, Pondicherry, Tamilnadu	ECR/451/Inst/PO/2013/RR-19	Pajanivel Ranganadin, MD	1) Lokesh Shanmugam, MD 2) Vimal Raj, MD	1) Kowshik Reddy 2) Subashri R 3) Soundariya 4) Selva Pandian 5) Agnus Panikar
Redkar Hospital and Research Centre, Pernem, Goa	ECR/902/INST/GA/2018	Sagar Redkar, MD	1) Vivek Redkar, MD 2) Supriya Redkar, MD 3) Shraddha Rane, MD	1) Tejaswini Patil 2) Mrunali Desai 3) Sarvesh Kerkar 4) Jyoti Patil 5) Dhananjay Lad
ESIC Medical College and Hospital, Haryana	ECR/167/Inst/HR/2013/RR-19	Anil Pandey, MD	1) Pooja Goyal, MD 2) Nidhi Anand, MBBS 3) Kranti Garg, MD	1) Dr. Bharti Gaur 2) Neha Katiyar 3) Soniya Chahal 4) Ayona James 5) Mohit Prajapati
Directorate of Public Health and Preventive Medicine, Chennai, Tamilnadu	ECR/270/Inst/TN/2013/RR-16	Selvavinayagam Sivaprakasam, MD	1) Palani Sampath, MBBS 2) Sudharshini Subramaniam, MD	1) Savitha Balaji 2) Roshini Azhaguvel 3) Parasuraman Palanivel 4) Sangliraj Muthukalai 5) Ayesha Bee
Sir Ganga Ram Hospital, New Delhi, Delhi	ECR/20/INST/DL/2013/RR-19	Anupam Sachdeva, MD	1) Manas Kalra, MD 2) Pooja Khosla, MD	1) Ajeet Nanda 2) Vinay Sharma 3) Rajni Singh 4) Sakshi Pandey 5) Priyanka Singh
Maharaja Agrasen Hospital, Jaipur, Rajasthan	ECR/745/INST/DL/2015/RR-18	Manish Jain, MD	1) Prabhat Sharma, MD 2) Deepak Sharma, MBBS	1) Kapil Soni 2) Khushwant Khatri

			3) Madhvender Jain, MD	3) Sanjeev Vimal 4) Gaurav Dalvi 5) Preshita Vanjare
Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana	ECR/293/Inst/HR/2013/RR-19	Savita Verma, MD	1) Dhruva Chaudhary, MD 2) Ramesh Verma, MD 3) Pawan Singh, MD	1) Deepak Gill 2) Anjali Ahlawat 3) Kavita 4) Bijender Singh 5) Rosy
Government Fever Hospital, Gorantla, Guntur	ECR/467/Inst/AP/2013/RR-19	S Laxmikumari, MD	1) D Sudheer, MD 2) P Basha, MD	1) Krishna Suri 2) Durga Anjali 3) G Divya 4) K Sowmya 5) K Jyothi
Aligarh Muslim University, Aligarh, Uttar Pradesh	ECR/1418/Inst/UP/2020	Mohammad Shameem, MD	1) Mansoor Tariq, MS	1) Mohammad Shiraz 2) Azimuddin Malik 3) Shafeequr Rahman 4) Nafees Khan 5) Samia Kirmani
Prakash Institute of Medical Science and Research, Islampur, Sangli, Maharashtra	ECR/1052/Inst/MH/2018	Vijaykumar Patil, MD	1) Pradeep Kulkarni, MBBS 4) B Patil, MD	1) Vishwajit Khade 2) Heyeshi Singh 3) Suhash Thorat
Rajashree Chhatrapati Shahu Maharaj Government medical college and Chhatrapati Pramila Raje Hospital, Kolhapur, Maharashtra	ECR/703/Inst/MH/2015/R-20	Sunita Ramanand, MD	1) Vijay Barge, MD 2) Varun Bafna, MD 3) Rama Bhosale, MD	1) Ratnadeep Patil 2) Shivani Patil 3) Suraj Shewale 4) Sadhana Jadhav 5) Nupur Shevale
<u>Bharat Biotech Clinical Team:</u> Shashi Kanth Muni, BDS Sapan Kumar Behera, MD Yuvraj Jogdand, MD Bhargav Reddy Dalta, PharmD Mr. Sunil Kumar Kantheti Ms. Sandhya Rani Nandala Ms. Aparna Bathula Ms. Amaravani Pittala Mr. Little Master Reddy Mr. Ashok Sudamala Mr. Nagaraju Pillutla Mr. Hrishikesh Reddy Ms. Akhila Naidu			<u>ICMR-National Institute of Virology:</u> Anita Shete-Aich, PhD Gururaj Deshpande, PhD Dr. Vinita Malik, PhD Mrs. Sheetal Kadam, MSc Prof. (Dr.) Priya Abraham, MD, PhD <u>Indian Council of Medical Research:</u> Samiran Panda, PhD Swati Gupta, PhD	

20 **Reverse transcription polymerase chain reaction (RT-PCR)**

21 The ICMR-NIV 2019-nCoV Assay Kit 3.1 contains a set of TaqMan RT-PCR assay for the qualitative
 22 detection and characterisation of SARS-CoV-2 RNA. The assay kit uses TaqMan Fluorogenic probe-
 23 based chemistry that uses the 5' nuclease activity of Taq DNA polymerase and enables the detection
 24 of a specific PCR product as it accumulates during PCR cycles.

25 The assay includes three targets E gene, ORF 1ab, RdRp of SARS-CoV-2 genes, and one house keeping
 26 gene, the β -Actin gene. The assay has one screening and two confirmatory viral genomic region
 27 targets, reducing the risk of false negatives.

28 The assay runs for 40 cycles; however, for any interpretation, the threshold cut off cycle Ct is 35.

29 **Results Interpretation is as follows:**

Target	E	ORF	RdRp	β -Actin
Positive	+	+	+/-	+
Negative	-	-	-	+
Strong* Positive (Very low Ct)	+	+	+	-
Sample quality poor	-	-	-	-
Inconclusive	+	-	-	+

30

31 Enzyme-linked immunosorbent assay (ELISA) at Screening

32 The National Institute of Virology (NIV) SARS-CoV-2 Human IgG ELISA kit is intended for qualitative
33 detection of IgG antibodies in serum/plasma of patients presenting clinical signs and symptoms
34 consistent with SARS CoV-2 infection or recovered patients. The sensitivity of the assay is 97.9%
35 percent and specificity 92.3% percent for Laboratory routine testing.

36 Each kit contains one vial of "Positive control" and one vial of "Negative control". These work as
37 markers of kit performance. P/N ratio of Positive control is defined as ratio of OD value of Positive
38 control divided by OD of average OD of Negative control. The test is considered to be valid if P/N
39 ratio is greater than 1.5.

40 Results are interpreted as follows:

- 41 • For an unknown sample (test sample) if O.D. value > Cutoff value and P/N ratio more than
42 1.5, sample should be considered as "Positive".
- 43 • For an unknown sample (test sample) if O.D. value < Cutoff value and P/N ratio less than 1.5,
44 sample should be considered as "Negative".

45

46 Enzyme-linked immunosorbent assays (ELISA) done at Bharat Biotech for lot-to-lot comparisons

47 ELISA tests were performed as per standard protocols. Briefly, microtiter plates were coated with
48 SARS-CoV-2 specific antigens: Whole inactivated SARS CoV-2 antigen; spike (S1) (Syngene,
49 Bangalore, India, Batch No# PRB026913); Receptor Binding Domain (RBD) (Syngene, Bangalore,
50 India, Batch No#PRB025485); nucleocapsid (N) (Syngene, Bangalore, India, Batch No# PRB025627) at
51 a concentration of 1µg/ml, 100µl/well in PBS pH 7.4). After overnight incubation, wells were blocked
52 and serially diluted sera added. After incubation, goat anti-Human IgG HRP conjugate (Sigma-Aldrich,
53 Cat# A8667, dilution 1:5000) was added and incubated for 1 hr at RT. Tetramethyl benzidine was
54 used as a substrate and absorbance measured at 450/630nm. Threshold value (Mean + 3 SD) was
55 established by taking the absorbance of Day 0 sera and antigen-specific endpoint titers were
56 determined for Day 56 sera samples. The reciprocal antibody dilution, at which absorbance is above
57 the threshold, was taken as antigen-specific antibody endpoint titers. All methods were validated
58 with respect to sensitivity and specificity.

59 Known unvaccinated and uninfected individual sera were used as a negative controls.

60 Simultaneously, ELISA blank (without coating antigen) was also maintained as a negative control.

61 Apart from this, cut off (Mean+3 SD) was drawn from the absorbance obtained at various dilutions
62 (1:1000 to 1:32000) of sera collected on day 0 (before vaccination) which had been found negative
63 in the RT-PCR and serology tests.

64 Next-Generation Sequencing

65 We were able to collect additional Nasopharyngeal swabs (NP) swabs from symptomatic Covid-19
66 (diagnosed by RT-PCR) participants who provided additional consent. All of the sequences were
67 generated by the ICMR-National Institute of Virology (NIV), Pune, India using a next-generation
68 sequencing approach. Controls were checked to ensure no evidence of amplification in the negative
69 tests and that expected RNA quantification was consistent with cycle threshold (Ct) values provided
70 by the testing laboratories.

71 All samples were processed by NIV laboratory staffs who were masked to vaccine allocation. In brief,
72 the total RNA was extracted from 200-400 µl of the SARS-CoV-2 real-time RT-PCR positive samples.
73 Extracted RNA was quantified using a Qubit RNA High Sensitivity (HS) kit by Qubit® 2.0 Fluorometer
74 (Invitrogen, Life Technologies). Samples having CT values below 25 were selected for further
75 processing with NGS. A total of 208 primers (104 for Pool#1 and 104 for Pool #2) were designed
76 using the Primal Scheme online tool covering the entire genome of the SARS-CoV-2. A multiplex RT-
77 PCR using the Superscript IV PCR kit (Invitrogen) was performed under the following conditions: 50°C
78 for 30 min; 98°C: 2 min; 35 cycles of 98°C for 10 sec, 56°C for 100 sec, and 72°C for 30 sec and final
79 extension at 72°C for 5 min. The PCR products obtained were loaded (25 µl) onto a 2% Agarose gel
80 and checked for the presence of a PCR product of the desired size.

81 Bands of around 400 bp were observed in all the Pool 1 and Pool 2 PCR products of samples. Gel
82 extraction of DNA bands was performed using the QIA quick DNA extraction kit protocol. This gel-
83 purified DNA product was used for the library preparation from the A-tailing step by Illumina Truseq
84 LT kit as described earlier (Nyayanit et al, 2020; Yadav et al, 2021). Libraries were quantified using
85 KAPA Library Quantification Kit (Kapa Biosystems, Roche Diagnostics Corporation, USA). Equimolar
86 ratios of libraries were pooled and denatured with 0.1 N NaOH and were neutralised using 0.1 M Tris
87 (pH7.0). The denatured libraries were diluted to 1.3 picomole using hybridization buffers before
88 loading onto Illumina Next seq 550 mid-outputs 300 cycles' reagent cartridges. CLC genomics
89 workbench version11.0 (CLC, QIAGEN, and Germany) was used for the analysis of the data
90 generated from the machine. Reference-based mapping was performed to retrieve the sequence of
91 the SARS-CoV-2.

92 *Nyayanit DA, Sarkale P, Baradkar S, et al. Transcriptome & viral growth analysis of SARS-CoV-2-*
93 *infected Vero CCL-81 cells. Indian J Med Res 2020; 152:70–6.*

94 *Yadav PD, Potdar VA, Choudhary ML, et al. Full-genome sequences of the first two SARS-CoV-2*
95 *viruses from India. Indian J Med Res 2020; 151: 200–9.*

96 Microneutralisation immunogenicity assay method (MNT₅₀)

97

98 A microneutralisation assay (MNT₅₀) was done at Bharat Biotech for the immunological lot to lot
99 comparisons.

100 The sera collected from all enrolled participants were inactivated at 56°C in a water bath for 30 min.

101 Sera were successively diluted in a two-fold series from a starting dilution of 1:8 to the required

102 concentration, and an equal volume of challenge virus solution containing 100 CCID₅₀ viruses was

103 added. After neutralisation in a 37°C incubator for two hours, a 1.0×10^5 /mL cell suspension was

104 added to the wells (0.1 mL/well) and cultured in a CO₂ incubator at 37°C for 3–5 days. The method

105 of Ramakrishnan (2016) was used applied to observations of the cytopathic effect (CPE) to

106 calculate the neutralisation endpoint (MNT₅₀) converting to logarithm the serum dilution that

107 protects 50% of cells from infection by challenge with 100 CCID₅₀ virus.

108

109 During each assay, a known antibody titre is used as a positive control, and pre-immune sera are

110 used as a negative control.

111

112 *Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol 2016;*

113 *5:85–6.*

114

115 ELISA assays for IgG against SARS-Cov-2 epitopes

116 The National Institute of Virology (NIV) SARS-CoV-2 Human IgG ELISA kit is intended for qualitative
117 detection of IgG antibodies in serum/plasma of patients presenting clinical signs and symptoms
118 consistent with SARS CoV-2 infection or recovered patients. The sensitivity of the assay is 97.9%
119 percent and specificity 92.3% percent for Laboratory routine testing.

120 Each kit contains one vial of "Positive control" and one vial of "Negative control". These work as
121 markers of kit performance. P/N ratio of Positive control is defined as ratio of OD value of Positive
122 control divided by OD of average OD of Negative control. The test is considered to be valid if P/N
123 ratio is greater than 1.5.

124 Results are interpreted as follows:

- 125 • For an unknown sample (test sample) if O.D. value > Cutoff value and P/N ration more than
126 1.5, sample should be considered as "Positive".
- 127 • For an unknown sample (test sample) if O.D. value < Cutoff value and P/N ration less than
128 1.5, sample should be considered as "Negative".

129 Enzyme-linked immunosorbent assays (ELISA) done at Bharat Biotech for lot-to-lot comparisons

130 ELISA tests were performed as per standard protocols. Briefly, microtiter plates were coated with
131 SARS-CoV-2 specific antigens: Whole inactivated SARS CoV-2 antigen; spike (S1) (Syngene,
132 Bangalore, India, Batch No# PRB026913); Receptor Binding Domain (RBD) (Syngene, Bangalore,
133 India, Batch No#PRB025485); nucleocapsid (N) (Syngene, Bangalore, India, Batch No# PRB025627) at
134 a concentration of 1µg/ml, 100µl/well in PBS pH 7.4). After overnight incubation, wells were blocked
135 and serially diluted sera added. After incubation, goat anti-Human IgG HRP conjugate (Sigma-Aldrich,
136 Cat# A8667, dilution 1:5000) was added and incubated for 1 hr at RT. Tetramethyl benzidine was
137 used as a substrate and absorbance measured at 450/630nm. Threshold value (Mean + 3 SD) was
138 established by taking the absorbance of Day 0 sera and antigen-specific endpoint titers were
139 determined for Day 56 sera samples. The reciprocal antibody dilution, at which absorbance is above
140 the threshold, was taken as antigen-specific antibody endpoint titers. All methods were validated
141 with respect to sensitivity and specificity.

142 Known unvaccinated and uninfected individual sera were used as a negative controls.


143 Simultaneously, ELISA blank (without coating antigen) was also maintained as a negative control.

144 Apart from this, cut off (Mean+3 SD) was drawn from the absorbance obtained at various dilutions
145 (1:1000 to 1:32000) of sera collected on day 0 (before vaccination) which had been found negative
146 in the RT-PCR and serology tests.

Supplementary table 2: Participants disposition status			
Description	BBV152 (N=12,899) n (%)	Placebo (N=12,899) n (%)	Total (N=25,798) n (%)
Screened Participants			26028
Screen Failure			217
Screened but not enrolled			13
Enrolled Participants	12899 (100)	12899 (100)	25798 (100)
Ongoing Participants	12194 (94.5)	12063 (93.5)	24257 (94.0)
Randomisation Analysis Set ^a	12899 (100)	12899 (100)	25798 (100)
Full Analysis Set (FAS) ^b	8946 (69.4)	8988 (69.7)	17934 (69.5)
Per-protocol Analysis Set (PP) ^c	8471 (65.7)	8502 (65.9)	16973 (65.8)
Immunogenicity Analysis Subset ^d	428 (3.3)	141 (1.1)	569 (2.2)
Safety Analysis Set ^e	12879 (99.8)	12874 (99.8)	25753 (99.8)
Category of Site			
Category 1 (Symptomatic)	8102 (62.8)	8375 (64.9)	16477 (63.9)
Category (Symptomatic/Asymptomatic)	4348 (33.7)	4373 (33.9)	8721 (33.8)
Category 3 (Symptomatic/Asymptomatic + Immunogenicity)	449 (3.5)	151 (1.2)	600 (2.3)
Visit 1 Completed	12,899 (100)	12,899 (100)	25,798 (100)
Visit 2 Completed	12,310 (95.4)	12,310 (95.4)	24,620 (95.4)
Visit 3 Completed	12,054 (93.5)	12,086 (93.7)	24,140 (93.6)
Visit 4 Completed	11,909 (92.3)	11,893 (92.2)	23,803 (92.3)

- 147 (a) All randomised participants classified according to the study product (vaccine or placebo) to which they
148 were randomised.
- 149 (b) All randomised participants who received at least one dose of IP and had no immunologic evidence of prior
150 COVID-19 (i.e, negative against SARS-CoV-2 antibodies) at Visit 1 before the first dose of IP. Participants will
151 be analysed according to the study product (vaccine or placebo) received.
- 152 (c) All participants in the FAS who received planned doses of IP per schedule, seronegative for SARS-CoV-2
153 antibody by ELISA at baseline, and had no major protocol deviations, as determined, and documented by
154 the Sponsor.
- 155 (d) Designated participants at study sites included in the immunogenicity study (category 3) who had received
156 both doses of IP and had no major protocol deviations.
- 157 (e) The Safety Set consists of all randomised participants who received at least one dose of IP, classified
158 according to the study product received.
- 159 % = n/N *100 where N = number of enrolled participants and n = number of participants.
- 160 Database cut-off date: 17 May 2021

161 **Figure 1.** Geometric mean ratios of MNT₅₀ for three consecutive manufacturing lots of BBV152
 162



163
 164
 165 Lot-to-lot consistency between treatments was declared if for all lot-to-lot comparisons, the two-
 166 sided 95% CI for the GMC ratio was completely contained within 0.5 and 2.0.

167

168

Supplementary table 3: MNT₅₀ neutralising antibody titres (95% CI) at Day 56 by age and gender					
MNT₅₀		BBV152 (All lots) (N = 386)		Placebo (N = 119)	
		n	GMT (95% CI)	n	GMT (95% CI)
Age Group (years)	≥18–<60	334	129.9 (114.3, 147.6)	101	12.9 (10.1, 16.5)
	≤60	52	101.2 (70.0, 146.3)	18	19.1 (9.0, 40.5)
Gender	Male	238	118.2 (101.0, 138.3)	77	14.1 (10.4, 19.2)
	Female	148	138.4 (114.4, 167.3)	42	12.9 (8.8, 19.0)
SARS-CoV-2 IgG status at baseline	Negative	338	118.03 (104.0, 134.0)	99	11.9 (9.3, 15.2)
	Positive	48	194.3 (134.4, 280.9)	20	27.4 (14.0, 53.5)

169 Shown are geometric mean titres measured using the wild-type SARS-CoV-2 microneutralisation
 170 assay (MNT₅₀) in sera obtained at Day 56, 4 weeks after the second vaccination.

171

172

Supplementary table 4. Summary of adverse events						
	BBV152 (N = 12,879)		Placebo (N = 12,874)		Total (N = 25,798)	
	Events n	Participants n (%)	Events n	Participants n (%)	Events n	Participants n (%)
All Adverse Events	2930	1597 (12.4)	3029	1597 (12.4)	5959	3194 (12.4)
Solicited AEs						
Any solicited AE	1949	1223 (9.5)	1720	1136 (8.8)	3669	2359 (9.2)
Solicited AE within 7 days post dose 1	1151	809 (6.3)	994	702 (5.5)	2145	151 (5.9)
Solicited AE within 7 days post dose 2	798	568 (4.4)	726	548 (4.3)	1524	1116 (4.3)
Unsolicited AEs	981	489 (3.8)	1309	609 (4.7)	2290	1098 (4.3)
Serious Adverse Events	40	39 (0.30)	66	60 (0.47)	106	99 (0.38)
All Medically Attended Adverse Events (MAAEs)	475	301 (2.3)	548	319 (2.5)	1023	620 (2.4)
Immediate AEs (within 30 min post vaccination)						
Any immediate AE	14	12 (0.10)	29	23 (0.18)	43	35 (0.14)
Immediate AEs post dose 1	11	10 (0.08)	19	17 (0.13)	30	27 (0.10)
Immediate AEs post dose 2	3	3 (0.02)	10	8 (0.06)	13	11 (0.04)
All Adverse Events of Special Interest (AESI)	23	23 (0.18)	23	23 (0.18)	46	46 (0.18)

174 N = number of participants in the relevant population,
175 Events, n = number of individual events reported (one participant may have reported several AEs),
176 Participants, n = Number of participants reporting at least one event,
177 % = n participants with an event/N *100
178

Supplementary table 5. Incidences of solicited adverse events after each dose.						
Participants reporting solicited AEs within 7 days of vaccination, n(%)	BBV152 (N = 12,879)		Placebo (N = 12,874)		Total (N = 25,798)	
	Dose 1 n (%)	Dose 2 n (%)	Dose 1 n (%)	Dose 2 n (%)	Dose 1 n (%)	Dose 2 n (%)
Any Local AE	431 (3.35)	278 (2.16)	399 (3.10)	260 (2.02)	830 (3.22)	538 (2.09)
Pain	392 (3.04)	233 (1.81)	358 (2.78)	208 (1.62)	750 (2.91)	441 (1.71)
Erythema	33 (0.26)	21 (0.16)	26 (0.20)	25 (0.19)	59 (0.23)	46 (0.18)
Induration	32 (0.25)	18 (0.14)	26 (0.20)	18 (0.14)	58 (0.23)	36 (0.14)
Swelling	21 (0.16)	14 (0.11)	32 (0.25)	16 (0.12)	53 (0.21)	30 (0.12)
Any Systemic AE	331 (2.57)	231 (1.79)	247 (1.92)	205 (1.59)	578 (2.24)	436 (1.69)
Pyrexia	108 (0.84)	86 (0.67)	81 (0.63)	79 (0.61)	189 (0.73)	165 (0.64)
Fatigue	52 (0.40)	41 (0.32)	41 (0.32)	20 (0.16)	93 (0.36)	61 (0.24)
Chills	28 (0.22)	9 (0.07)	22 (0.17)	16 (0.12)	50 (0.19)	25 (0.10)
Headache	128 (0.99)	86 (0.67)	111 (0.86)	70 (0.54)	239 (0.93)	156 (0.61)
Myalgia	49 (0.38)	37 (0.29)	28 (0.22)	28 (0.22)	77 (0.30)	65 (0.25)
Arthralgia	17 (0.13)	12 (0.09)	17 (0.13)	17 (0.13)	34 (0.13)	29 (0.11)
Nausea	17 (0.13)	14 (0.11)	12 (0.09)	10 (0.08)	29 (0.11)	24 (0.09)
Vomiting	12 (0.09)	6 (0.05)	8 (0.06)	8 (0.06)	20 (0.08)	14 (0.05)

179 N = number of participants in the relevant population,
180 Events, n = number of individual events reported (one participant may have reported several AEs),
181 Participants, n = Number of participants reporting at least one event,
182 % = n participants with an event/N*100

183 Med